Categories: Technology

Mandatory disclosure of holding and notice of trade in IDEX Biometrics 23 July 2025

 | Source: IDEX BIOMETRICS ASA

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider.

Tranche 1 of the private placement amounted to 4,731,594 shares. As disclosed separately, Pinchcliffe AS, a company closely related to CEO and CFO Anders Storbråten, participated in the private placement and subscribed for 739,360 shares in Tranche 1.

In connection with the private placement, the manager of the private placement, IDEX Biometrics and Mr. Storbråten entered into a share lending agreement.

Mr. Storbråten has lent 4,731,594 shares, ISIN NO0013536078, in connection with the settlement of Tranche 1. The shares have been lent, not sold, and will be returned in due course. 

After the subscription by Pinchcliffe and the temporary lending of shares, Mr. Storbråten and close relations hold 6,503,476 or 12,48% shares of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1.

Contact person
Anders Storbråten, CEO and CFO
Tel: +47 4163 8582
E-mail: ir@idexbiometrics.com

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

For more information, visit www.idexbiometrics.com

About this notice
This notice was issued by Erling Svela, Vice president of finance, on 23 July 2025 at 11:50 CET on behalf of IDEX Biometrics ASA. The information about the lending shall be disclosed according to article 19 no. 3 of the EU Market Abuse Regulation (EU 596/2014). The information about shareholding shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA). The information is published in accordance with section 5‑12 of the Norwegian Securities Trading Act.

GlobeNews Wire

Recent Posts

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:05 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, Jan. 16, 2026 (GLOBE…

2 minutes ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:05 ET  | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE…

2 minutes ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am…

2 minutes ago

NeuroDyne Drops: Sharp Mind, Enhanced Memory, and Lasting Focus As Nature Intended, Ingredients

NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY…

9 hours ago

Optivell Officially Announced as a Vision Support Formula for Preventive Eye Wellness

New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- OPTIVELL INTRODUCED AS A NEW…

9 hours ago

Sugar Clean Drops: Top Blood Sugar Support Supplement for Metabolic Wellness and Energy Support

SUGAR CLEAN DROPS ANNOUNCED AS A NEW SUPPLEMENT SUPPORTING HEALTHY BLOOD SUGAR AND METABOLIC WELLNESS…

9 hours ago